

1 *Title:* Primate innate immune responses to bacterial and viral pathogens reveals an evolutionary
2 trade-off between strength and specificity

3

4 *Running Title:* Evolution of innate immune responses in primates

5

6 *Authors:* Mohamed Bayoumi Fahmy Hawash¹, Joaquin Sanz-Remón^{2,3}, Jean-Christophe
7 Grenier⁴, Jordan Kohn^{5,6}, Vania Yotova¹, Zach Johnson⁷, Robert E. Lanford⁸, Jessica F.
8 Brinkworth^{*9,10}, Luis B. Barreiro^{*11}.

9

10 *Affiliations:*

11 1. CHU Sainte-Justine, University of Montreal, Montreal, Canada, 2. Departamento de Fisica
12 Teórica, Universidad de Zaragoza, Zaragoza, Spain, 3. Institute BIFI for Biocomputation and
13 Physics of Complex Systems, Universidad de Zaragoza, Zaragoza, Spain, 4. Montreal Heart
14 Institute, University of Montreal, Montreal, Canada, 5. Department of Neuroscience, Emory
15 University, 6. Department of Psychiatry, College of Health Sciences, University of California
16 San Diego, United States, 7. Illumina, San Diego CA, United States, 8. Southwest National
17 Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
18 9. Department of Anthropology, University of Illinois Urbana-Champaign, United States, 10.
19 Carl R. Woese, Institute for Genomic Biology, University of Illinois Urbana-Champaign,
20 United States, 11. Department of Genetic Medicine, University of Chicago, Chicago, United
21 States

22

23

24

25

26

27 *Correspondence to Luis B. Barreiro (lbarreiro@uchicago.edu) or Jessica F. Brinkworth
28 (jfbrinkw@illinois.edu)

29

30 *Keywords:* Pathogen-associated molecular patterns, primate evolution, early immune
31 responses to infection, immunodeficiency viruses, Gram-negative bacteria

32

33 *Conflicts of Interest:* The authors have no conflicts of interest

34 **Abstract**

35 Despite their close genetic relatedness, apes and African and Asian monkeys (AAMs), strongly
36 differ in their susceptibility to severe bacterial and viral infections that are important causes of
37 human disease. Such differences between humans and other primates are thought to be a result,
38 at least in part, of inter-species differences in immune response to infection. However, due to
39 the lack of comparative functional data across species, it remains unclear in what ways the
40 immune systems of humans and other primates differ. Here, we report the whole genome
41 transcriptomic responses of ape species (human, common chimpanzee) and AAMs (rhesus
42 macaque and olive baboon) to bacterial and viral stimulation. We find stark differences in the
43 responsiveness of these groups, with apes mounting a markedly stronger early transcriptional
44 response to both viral and bacterial stimulation, altering the transcription of ~40% more genes
45 than AAMs. Additionally, we find that genes involved in the regulation of inflammatory and
46 interferon responses show the most divergent early transcriptional responses across primates
47 and that this divergence is attenuated over time. Finally, we find that relative to AAMs, apes
48 engage a much less specific immune response to different classes of pathogens during the early
49 hours of infection, upregulating genes typical of anti-viral and anti-bacterial responses
50 regardless of the nature of the stimulus. Overall, these findings suggest apes exhibit increased
51 sensitivity to bacterial and viral immune stimulation, activating a broader array of defense
52 molecules that may be beneficial for early pathogen killing at the potential cost of increased
53 energy expenditure and tissue damage.

54

55

56 INTRODUCTION

57 Despite being close evolutionary relatives, humans, chimpanzees and African and Asian
58 monkeys exhibit inter-species differences in sensitivity to and manifestation of certain bacterial
59 and viral pathogens that are major causes of mortality in humans (e.g. HIV/AIDS, Hepatitis C
60 Virus, broad range of commensal Gram-negative bacteria commonly implicated in sepsis).¹⁻⁵
61 Humans, for example, are highly sensitive to stimulation by the Gram-negative bacterial cell
62 wall component hexa-acylated lipopolysaccharide (LPS), miniscule amounts of which (2-
63 4ng/kg) can provoke inflammation, malaise and fever, and a slightly higher dose, septic shock
64 (15 ug/kg).^{1,6,7} In contrast, baboons and macaques require doses nearly 10 fold higher in
65 concentration to trigger similar symptoms.^{5,8,9} Pattern recognition receptors (PRRs) such as
66 Toll-like receptors (TLRs) play a central role in the mediation of innate immune responses to
67 pathogens¹⁰. The limited number of studies comparing leukocyte function after stimulation
68 with TLR-detected pathogen-associated molecules (PAMPs) suggest that the differences in
69 infectious diseases susceptibility noted between apes and AAMs is, in part, the outcome of
70 lineage-specific evolution of early innate immune system regulation and signaling.¹¹⁻¹³ Indeed,
71 innate immune components responsible for detecting pathogens, including TLRs that sense
72 Gram-negative bacteria and single-stranded RNA viruses, have been found to be under positive
73 selection in primates.^{14,15}

74

75 Despite stark differences in the manifestation of severe infections between apes and African
76 and Asian monkeys (AAMs), there are few reports directly comparing the gene expression
77 response across species to bacterial and viral pathogens.^{11,12} Further, previous studies relied
78 mainly on isolated cell types to characterize immune responses across primates^{11,16}, which does
79 not faithfully reflect the nature of the innate immune response that is a product of the interaction
80 between several cell populations¹⁷. To better understand the evolution of the primate immune
81 system, this study compares the early responses of apes (humans and common chimpanzees)
82 and AAMs (rhesus macaques and olive baboons) to bacterial and viral stimulants. Here, we
83 report on the whole genome expression of total blood leukocytes from these four primate
84 species responding to bacterial and viral stimulation during the first 24 hours of challenge. Our
85 results show that apes and AAMs have diverged in sensitivity to specific microbial assaults,
86 such that ape leukocyte responses favor robust antimicrobial power over pathogen specificity
87 at the potential cost of increased energetic expenditure and bystander tissue damage.

88

89

90 Results

91

92 *Evolutionary relationships explain most of the transcriptional response variation in primates* 93 *to bacteria or viral stimulation*


94

95 To assess differences in innate immune function between higher order primates in as close an
96 approximation to *in vivo* as possible, we challenged whole blood from humans (*Homo sapiens*;
97 N=6), common chimpanzees (*Pan troglodytes*; N=6), rhesus macaques (*Macaca mulatta*;
98 N=6) and olive baboons (*Papio anubis*; N=8) with bacterial or viral *stimuli* via venous draw
99 directly into a media culture tube containing either lipopolysaccharide (LPS) from *Escherichia*
100 *coli* O111:B4, gardiquimod (GARD), a single-stranded RNA viral mimetic, or endotoxin-free
101 water, as a negative control (Control). Blood was stimulated for 4 and 24 hours before the total
102 leukocytes were isolated, and RNA extracted for RNA-sequencing (**Figure 1A**). We chose
103 these two molecules because in mammals they are broad signals of infection by pathogen types
104 for which there are well established differences in disease manifestation between apes and
105 AAMs (e.g., immunodeficiency viruses, Hepatitis C, common commensal bacteria that cause
106 Gram-negative bacterial sepsis).^{1,3,4} Following quality control filtering, we analyzed 151 high-
107 quality RNA-sequencing profiles across species and treatment combinations (see Methods,
108 **Table S1**). We focus our comparative analyses on the expression levels of 14,140 one-to-one
109 (1:1) orthologous genes, taking into account potential biases in expression estimates due to
110 differences in mappability between species (Methods).

111

112 As whole blood contains a variety of leukocyte cell subtypes, we first characterized differences
113 in total blood leukocyte composition between species using fluorescence-activated cell sorting
114 (FACS). Leukocyte composition differs between species for all major subtypes measured, with
115 the most notable differences an increase in the proportion of monocytes in humans (CD14⁺, P
116 < 0.003) and helper T cells in chimpanzees (CD3⁺, CD4⁺; $P = 0.0006$ to 0.065), relative to
117 other primates (**Figure 1B, Table S2**). Using linear models that account for variation in cell
118 composition, we next identified genes that respond to LPS and GARD in each of the species,
119 at each of the time points (see Methods). In all species, both treatments led to the up- or down-
120 regulation of hundreds to thousands of genes (FDR <0.05 , **Figure 1C, Table S3**). As expected,
121 the transcriptional response to either stimulus was highly concordant across primates
122 (Spearman's r range 0.5 to 0.87 across all pairwise comparisons; **Figure S1**), with stronger
123 correlations between closely related primates than between more distantly-related pairs of

124 species (e.g., at LPS 4 hours Spearman's r human vs chimpanzee = 0.84, human vs baboon =
 125 0.50). Consistently, the first principal component (PC) of the log₂ fold-change responses to
 126 both LPS and GARD accounted for ~20% of the total variance in our dataset and separated
 127 apes (human and chimpanzee) from AAM (macaque and baboon) (t-test; $P < 1 \times 10^{-10}$ for both
 128 4h and 24h, **Figure 1D**). The second PC captured differences in immune response to bacterial
 129 or viral stimulation (t-test; $P < 1 \times 10^{-8}$ for 4 and 24h; **Figure 1D**). We identified a set of 648
 130 and 257 genes that early after stimulation (4 hours) showed a consistently strong response
 131 across all species to LPS or GARD, respectively (defined as genes with $|\log_2 \text{FC}| > 1$ and FDR
 132 < 0.05 in all species, **Table S4**). These genes include most of the key transcription factors
 133 involved in the regulation of innate immune responses to bacterial (e.g., *NFKB1/2*) and viral
 134 pathogens (e.g., *IRF7/9*), as well as several effector molecules involved in the regulation of
 135 inflammatory responses to infection (e.g., *IL6*, *TNF α* and *IL1 β*).
 136



137
 138 **Figure 1. Characterizing innate immune response upon viral and bacterial stimulation of**
 139 **primate's white blood cells. (A)** Schematic representation of the study design. Whole blood
 140 samples from humans, common chimpanzees, rhesus macaques and olive baboons were
 141 stimulated with bacterial or viral *stimuli* via venous draw directly into a media culture tube
 142 containing either lipopolysaccharide (LPS), single stranded RNA viral mimetic gardiquimod
 143 (GARD), or endotoxin-free water, as a negative control (Control). At 4- and 24-hours post-
 144 stimulation white blood cells were isolated, and RNA extracted for RNA-sequencing. **(B)** Cell
 145 proportion of 6 populations of innate immune cells for all species. Species are indicated on x
 146 axis and proportions this population from total leukocytes is on y axis. Abbreviations are PMNs

147 for polymorphonuclear cells and Natural killer for NK cells (**C**) Number of differentially
148 expressed genes (DEGs; FDR<0.05) in response to LPS (top panels) and GARD (bottom
149 panels) in each of the species at 4- and 24-hours post-stimulation The exact number of up- and
150 down-regulated genes in each condition in each species are indicated on the bar charts. (**D**)
151 Principal component analyses (PCA) performed on the log₂ fold-change responses observed
152 at 4 hours post LPS and GARD stimulation. PC1 primarily separates apes (human and
153 chimpanzee) from AAM (macaque and baboon), and PC2 captures differences in immune
154 response to bacterial or viral stimulation.

155

156


157 ***Stronger early innate immune response in apes than in AAM***

158

159 Next, we sought to characterize differences in immune responses across species. To do so, we
160 first looked at overall differences in the magnitude of the transcriptional responses to LPS and
161 GARD across species (see Methods). We found that, at early time points, both ape species
162 (human and chimpanzee) engage a much stronger transcriptional response to both stimuli as
163 compared to rhesus and baboons (in average ~2-fold higher, Wilcoxon test $P < 10^{-10}$, **Figure**
164 **2A**). Next, we identified genes for which the magnitude of the transcriptional response to LPS
165 or GARD was significantly different between apes and AAM (FDR<0.10 for *all* pair-wise
166 contrasts between an ape and an AAM species and an average $|\log_2 \text{FC}| > 0.5$). Hereafter, we
167 refer to these genes as Clade Differentially Responsive Genes, or c-DRGs. We identified a total
168 831 and 443 c-DRGs, in the early response (4 hours) to LPS and GARD, respectively (**Figure**
169 **2B, Table S5**). Among c-DRGs, 83-92% showed a stronger response in apes as compared to
170 AAM, consistent with the genome-wide pattern of an overall more robust transcriptional
171 response to immune stimulation in apes. Importantly, the stronger response observed in apes is
172 not explained by higher baseline expression levels of the receptors involved in the recognition
173 of LPS (*TLR4*, *CD14*, *LY96* and *CASP4*) and GARD (*TLR8*) (**Figure S2**). Next we focused
174 our analyses on a manually curated list of 1079 genes belonging to different modules of the
175 innate immune system¹⁸ and that were found to change gene expression in at least one of our
176 experimental conditions, in at least one of the species from our dataset. These genes include
177 sensors (n=188), adaptors (n=36), signal transducers (n=209), transcription (factors) (n=74),
178 effector (molecules) (n=115), accessory molecule (n=54) and secondary receptors (n=50). All
179 modules show similar divergence between clades, with ~15% of the genes within each module
180 classified as c-DRGs with a stronger response in apes, as compared less than 5% showing a
181 significantly stronger response in AAM (**Figure 2C**).

182

183 To further characterize functional differences in immune regulation between apes and AAM
 184 we devised a new score of transcriptional divergence at the pathway level. We focused on the
 185 set of 50 “hallmark pathways”, which capture well-defined and curated biological states or
 186 processes.¹⁹ Briefly, for each gene in these pathways, a divergence score between apes and
 187 AAM was computed by calculating the average difference between the fold-change estimates
 188 between all pairs of species of the two clades, while taking into account variance in
 189 transcriptional response within each species. The pathway divergence score reflects the average
 190 divergence scores across all genes of a given pathway (see Methods for details). In the early
 191 response to LPS, the most divergent pathways between apes and AAM were “Interferon alpha
 192 response” and “Interferon gamma response” ($P \leq 0.01$, **Table S6**), indicating that the regulation
 193 of interferon responses has significantly diverged since the separation between apes and AAM.
 194 In the early response to GARD, pathways directly related to the regulation of inflammatory
 195 responses, notably TNF- α signaling, were the most divergent ($P \leq 0.01$) (**Figure 2D**).
 196



197
 198 **Figure 2. Stronger early innate immune response in apes than monkeys.** (A) For each
 199 combination of stimulus and time-point we show the distribution of the log₂ fold changes (x-
 200 axis) among genes that respond to that treatment in at least one of the species. The median
 201 log₂ fold change responses in each species is represented by a dashed line. (B) Number of
 202 differentially responsive genes that are clade- or species-specific differently regulated genes at
 203 4 hours post LPS (left) and GARD (right) stimulation. For clade differently regulated genes (c-
 204 DRG) we report number of genes that show a stronger response in specific clade at the
 205 beginning of ancestral branch of the tree. For example, in response to LPS we identified 831
 206 c-DRGs from which 728 show a stronger response in apes and 103 in AAMs. For species-
 207 specific responsive genes numbers are given in front of each species. The color codes for each
 208 species are red for human, cyan for chimp, orange for baboon and violet for macaque. (C) Bar

209 plots represent the proportions of different classes of innate immunity genes that are classified
210 as c-DRGs with a higher response in apes (dark violet) or in AAMs (dark blue). **(D)** Scatter
211 plot displaying total divergence scores of hallmark pathways for LPS (green) and GARD (pink)
212 at 4h stimulations. For a given pathway, the total divergence is given by divergence score (DS)
213 on the x-axis and $-\log_{10}$ p values for each DS is on the y-axis. The pathways names, DS values,
214 and corresponding p values are shown in **Table S6**. We highlight the pathways showing the
215 most significant divergence scores for both the response to LPS and GARD.

216
217

218 *Species-specific immune responses reflect unique immune regulation mechanisms and* 219 *lineage-specific divergence*

220


221 Next, we sought to identify genes that respond to immune stimulation in a species-specific
222 fashion. These were characterized as genes for which the magnitude of the response to LPS or
223 GARD in one species was significantly different to that observed in all other species (see
224 Methods). Across time-points and immune stimulations we identified a total of 980, 726, 425
225 and 655 species-specific responsive genes in human, chimpanzees, macaques and baboons,
226 respectively (**Table S7**). Among baboon-specific responsive genes the vast majority (69%)
227 showed a weaker magnitude of the response to 4-hours of LPS stimulation in baboons as
228 compared to all other primates (**Table S7**). Gene ontology (GO) enrichment analyses (**Table**
229 **S8**) revealed that these genes were enriched among defense response genes ($FDR = 4.8 \times 10^{-14}$)
230 and a variety of other GO-associated immune terms (**Figure 3B**), including several key
231 transcription factors (e.g., *STAT1*, *IRF7/9*), major inflammatory cytokines (e.g., *IL1B* and
232 *CXCL8*), and a number of genes directly involved in LPS sensing and recognition (adaptor
233 molecules *IRAK2*, *3* and *4*, and the primary LPS receptor, *TLR4*) (**Figure 3A**; **Table S7**). The
234 weaker response observed in baboons appears to be, at least in part, due to a higher baseline
235 expression level of many of these innate immunity genes (**Figure S3**). Baboons have been
236 suggested to bear higher pathogen loads than apes due to their mating promiscuity, and so it is
237 tempting to speculate that increased baseline might represent a mechanism of protection against
238 frequent microbial infections.^{20,21} In rhesus macaques, the other AAM species, genes showing
239 a stronger response to LPS at both 4 and 24 hours than that observed in all other species
240 (N=157, **Table S7**) were mostly enriched among genes involved in the regulation of
241 inflammatory responses ($FDR = 0.002$, **Table S8**), including *TREM2* a known suppressor of
242 PI3K and NF-kappa-B signaling in response to LPS.

243

244 Among chimpanzees-specific genes the most notable GO enrichments were observed among
245 genes showing a weaker response to LPS at 24 hours relative that observed in all other primates.
246 These genes were significantly enriched for GO terms associated with viral defense
247 mechanisms, including “response to virus”, or “type I interferon signaling pathway”
248 (FDR<1x10⁻⁹, **Figure 3C**). Further inspection of these genes revealed that the vast majority are
249 strongly up-regulated at 4 hours post-LPS stimulation – at similar levels to those observed in
250 other species - but that chimpanzees have a unique ability to shutdown these genes at later time
251 points. For example, the prototypic interferon responsive gene *MXI* is up-regulated by over 5-
252 fold in all primates at 4 hours but by 24 hours *MXI* levels have revert to baseline uniquely in
253 chimpanzees (**Figure 3E**), suggesting that chimpanzees are particularly divergent in the
254 regulatory circuits associated with the control of viral responsive genes.

255
256

257 In contrast to the pattern observed for baboons, human-specific responses were associated with
258 genes showing a stronger response to immune stimulation as compared to that observed in
259 other primates. Gene ontology analyses revealed that these genes are over-represented among
260 terms related to the regulation of cytokine production involved in immune response (FDR =
261 0.045), and T cell activation involved in immune response (FDR = 0.06) (**Table S8**). Notable
262 examples of human-specific responding genes include the canonical T cell co-stimulatory
263 molecule CD80 (average 5-fold increase in response to both stimuli relative to other species)
264 and *IFN γ* , a cytokine central for protective immunity against a large number of infectious
265 agents and the key determinant of the polarization of T cells towards a pro-inflammatory Th1
266 phenotype²² (**Figure 3D**). The higher production of *IFN γ* and *CD80* in humans may mediate
267 more effective killing of viral and bacterial pathogens. Further, as these molecules are
268 important regulators of cytokine production and T cell activation, it also suggests significantly
269 different regulation of T cell responses.^{23,24}



270
 271 **Figure 3. Species specific immune response reflect unique immune regulation**
 272 **mechanisms and lineage specific divergence. (A)** Circos plots showing different classes of
 273 innate immune genes (clustered using different color codes) classified as species-specific
 274 responsive at 4 hours post-LPS stimulation in humans (left) and baboons (right). The log2FC
 275 key represent the average difference between species response versus all other species where
 276 the positive (red color) and negative (blue) values indicate the magnitude of the stronger and
 277 weaker absolute response in this species vs. all others, respectively. **(B)** Gene ontology (GO)
 278 enrichment analysis for genes showing an weaker response to LPS at 4 hours in baboons as
 279 compared to all other species. **(C)** Gene ontology (GO) enrichment analysis for genes showing
 280 an weaker response to LPS at 24 hours in chimpanzees as compared to all other species. For B
 281 and C only top GO terms are presented. The full list of significant GO terms can be found in
 282 **Table S8. (D)** Boxplot represent the log2FC of *IFN γ* and *CD80* genes which, at 4 hours post-
 283 LPS stimulation, were found to have a significantly stronger response in human than in other
 284 primates. **(E)** Estimates of the mean fold changes response for *MX1* (+/- SE) at the two time
 285 points across the four primate species studied.


286
 287

288 *Regulatory divergence decreases as infection proceeds*

289

290 Next, we compared the transcriptional divergence between early (4 hour) and late (24 hours)
 291 immune responses. We observed a marked reduction in divergence scores at 24 hours post-
 292 stimulation of most hallmark pathways in the response to both LPS ($P=8 \times 10^{-6}$) and GARD
 293 ($P=6 \times 10^{-9}$) (**Figure 4A**). In LPS-stimulated cells, the most striking differences were observed

294 for interferon-related pathways, which show a reduction in divergence score of ~6-fold
 295 between the two time points. In GARD-simulated cells, the largest reduction in divergence
 296 scores was observed among pathways related to the regulation of inflammatory responses
 297 (**Figure 4A**). These findings indicate that most transcriptional divergence in immune responses
 298 among primates occurs during the initial response to pathogens followed by an overall
 299 convergence to similar response levels at later time point, specifically among genes involved
 300 in the regulation of inflammation and viral-associated interferon responses (**Figure 4B**). In
 301 apes (but not in AAMs), genes involved in the regulation of inflammation are strongly enriched
 302 among those for which the response to GARD significantly decreases at the later time point,
 303 whereas those decreasing in response to LPS are enriched for viral response genes (**Figure 4C**;
 304 **Table S9**).



305
 306 **Figure 4. Divergence of immune response is reduced at later time point.** (A) Scatter plots
 307 of divergence scores of hallmark pathways at early (x-axis) and later time points (y-axis) for
 308 LPS (green) and GARD (maroon) stimulations. The inset boxplots contrast the distribution of
 309 divergence scores among all pathways between the two time points. P values were obtained

310 using Mann Whitney test. **(B)** Estimates of the mean response at the two time points for each
311 species (+/- SE) across genes bellowing to the interferon alpha and inflammatory response
312 hallmark pathways. **(C)** GO enrichment analysis for genes that showed significant decrease in
313 response in apes only (FDR < 0.05 in apes and FDR > 0.05 in monkeys) for LPS and GARD.
314 Top significant GO terms are given as indicated by $-\log_{10}$ p value on the x axis.
315

316

317 *Apes engage a less specific innate immune response than AAM*

318 An aspect of innate immunity central to its success during microbial assault is its ability to
319 recognize pathogens and initiate the most appropriate defense against them by type. The
320 specificity of the innate immune response to infection is mediated by pattern recognition
321 receptors that detect the presence of danger signals via conserved molecular patterns associated
322 with subtypes of pathogens and host damage (e.g. penta- and hexa-acylated LPS from Gram-
323 negative bacteria detected by *TLR4-LY96* receptors).^{25,26} Signals of viral danger such as GARD
324 are expected to activate a response mainly controlled by transcription factors prominent in
325 antiviral defense such as interferon regulatory factors (IRFs), which limit viral replication and
326 dissemination through the upregulation of interferons and interferon-regulated genes.^{27,28} By
327 contrast, recognition of Gram-negative bacteria via cell-wall component LPS stimulates a
328 broader array of cytokine responses that tends towards expression of pro-inflammatory
329 cytokines regulated by transcription factors *NFκB* and *API*, but can also include interferon
330 expression regulated by transcription factors such as *IRF3* and JAK-STAT.^{27 29-31}


331 Two major lines of evidence indicate that early transcriptional immune responses are less
332 specific in apes than in AAM. First, we found the transcriptional responses to LPS and GARD
333 were more similar to each other in apes (humans $r = 0.87$, chimpanzees $r=0.83$) than they were
334 in baboons ($r = 0.44$) or macaques ($r = 0.65$) (**Figure 5A**). Accordingly, we found about three
335 times more genes that respond *uniquely* to either LPS or GARD (i.e., “ligand specific” genes)
336 in AAM as compared to apes (χ^2 test; $P=2.2 \times 10^{-16}$) (**Figure 5B**, Methods for details on the
337 statistical model used to characterize ligand specific and shared genes). The second piece of
338 evidence comes from the nature of the genes that are differentially activated in response to LPS
339 and GARD. The fact that apes show a higher correlation in GARD and LPS responses
340 compared to AAMs predicts that they will tend to activate both antibacterial and antiviral
341 defenses mechanisms regardless of the nature of the stimuli. Supporting this notion, the genes
342 that exhibited a stronger response in apes than in AAMs after stimulation with the viral mimic
343 GARD for four hours were most significantly enriched genes involved in the regulation of

344 inflammatory responses ($P= 7.1 \times 10^{-6}$; FDR = 0.008, **Table S8**), whereas genes involved in the
345 response to viruses (GO term “response to virus”) were enriched upon bacterial LPS
346 stimulation ($P= 0.0023$; FDR = 0.15, **Table S8**).

347

348 To explore these differences in more detail, we focused on genes involved in the interferon
349 alpha pathway (viral-associated response) or inflammatory response (bacterial-associated
350 response). In AAMs, inflammatory response genes tended to be more strongly up-regulated in
351 response to LPS compared to GARD ($P \leq 0.0027$), suggesting that their transcription is
352 particularly sensitive to receipt of a bacterial danger signal compared to a viral one. No
353 significant differences in upregulation of these same genes were noted between LPS and
354 GARD cells in apes (**Figure 5C**). For example the canonical pro-inflammatory cytokine
355 *TNF*, which in macaques and baboons is strongly up-regulated only in response to LPS, is
356 potently up-regulated in response to both stimuli in humans and chimpanzees (by over ~4-
357 fold, **Figure 5D**). Other examples of this pattern include the classical pro-inflammatory
358 cytokines *IL1A* and *IL1B* (**Figure S4**). Likewise, interferon-associated genes were more
359 strongly up-regulated in response to GARD compared to LPS in AAM ($P \leq 7.7 \times 10^{-6}$), while
360 in apes these genes showed more concordant levels of up-regulation between stimuli (**Figure**
361 **5C**). Interferon-induced and potent antiviral genes, including *MX1* and *OAS1*, were much more
362 strongly upregulated in response to GARD than to LPS in AAMs compared to apes (**Figure**
363 **S4**).

364



365
 366 **Figure 5. Apes engage a less specific innate immune response than AAMs.** (A) Correlation
 367 plots of the magnitude of the fold change responses between LPS (x-axis) and GARD-
 368 stimulated cells (y-axis). For each of the species, we only include genes that were differentially
 369 expressed (FDR < 0.05) in response to at least one of the stimuli (N= 7862, 7874, 6585 and
 370 5430 genes for human, chimp, baboon and macaque, respectively). High correlation was found
 371 in apes (~ 0.85) while modest correlation was found in baboon (0.44) and moderate in macaque
 372 (0.65). (B) Proportion of ligand-specific (i.e., genes that respond uniquely to either bacterial or
 373 viral stimuli) and shared genes (i.e., genes equally activated by both immune stimuli) across
 374 species. (C) Violin plots comparing (scaled) log₂ fold-change responses to 4 hours of LPS and
 375 GARD stimulation between genes belonging the hallmark pathways “Interferon (IFN) alpha”
 376 and “inflammatory response”. The p-values shown have been Bonferroni corrected for the
 377 number of tests performed. “NS” stands for non-significant (i.e., p value > 0.05) (D) Boxplots
 378 of the log₂ fold change response (y-axis) of *TNF* in response to LPS and GARD stimulations
 379 across primates.
 380
 381
 382
 383

384 **Discussion**

385 Our study provides a genome-wide functional comparison of variation in innate immune
386 responses between species belonging to two closely related clades of primates. Ape (human
387 and chimpanzee) total blood leukocytes were significantly more responsive to bacterial and
388 viral stimulation compared to total blood leukocytes obtained from AAM (rhesus macaques
389 and baboons) during the early hours of challenge, mounting generally stronger and less specific
390 transcriptional responses. This increased response suggests apes maintain increased sensitivity
391 to particular types of microbial assaults compared to AAM, a phenomenon likely to come with
392 considerable energetic cost.^{1,5} From an evolutionary standpoint investment in increased
393 sensitivity to pathogens can limit the negative effects of pathogen exposure on reproductive
394 fitness. Humans and chimpanzees participate in a comparatively slower life history than rhesus
395 macaque and olive baboon monkeys – they live decades longer, take longer to reach sexual
396 maturity, nurture their young longer and maintain a larger body size³²⁻³⁴. A long life at a large
397 size increases risk of pathogen exposure both in terms of number of exposures and absolute
398 load, over the course of a life that will have long periods of time between the birth of offspring.
399 A slow life history strategy can be concomitant with and increase risk in pathogen-mediated
400 limitations in reproductive success, making a more substantial investment in robust early
401 pathogen detection and elimination evolutionarily beneficial, compared to the ordinary
402 metabolic costs of launching those responses.^{35,36}

403

404 However, serious bystander tissue damage is a cost for immune protection during severe
405 infections. Pathogen virulence may play a significant role in the evolution of high energy low
406 specificity early immune responses. The primate genera in this study substantially differ in
407 their evolutionary exposure to particular pathogens (e.g. dengue virus, immunodeficiency
408 viruses, Zika virus)³⁷⁻⁴⁰. Exposure to pathogens of high virulence may lead to a low cost-benefit
409 ratio for primate hosts, since the reproductive and evolutionary benefit of a transiently
410 demanding immune response outweighs its energetic and tissue costs.^{41,42} Under this rubric,
411 a robust but less specific early response to pathogens is effective and beneficial most of the
412 time. Any contribution that response might make to immunopathology in apes through
413 potentially increased risk of sepsis or chronic inflammatory disease is evolutionarily negligible
414 compared to the persistent risk of infection. Interestingly, among the most divergently
415 responding pathways between apes and AAMs, several were associated with the regulation of
416 interferon responses and responses to viruses. These findings are consistent with growing body

417 of literature that pathogens and, specifically, viruses have been important drivers of adaptive
418 evolution in humans and other mammals.^{15,43-45}

419

420 Regardless of initial strength and divergence of transcriptional response to LPS and GARD,
421 we show that the transcriptional activity of antiviral (interferon) and inflammatory pathways
422 became attenuated over time and more similar between species. While acute-phase and early
423 proinflammatory responses are typically later countered by a later anti-inflammatory response
424 to lessen host damage and maintain homeostasis, the dampening of this initial powerful
425 antimicrobial response over time, is profound⁴⁶. Remarkably, in apes the pathways that
426 underwent the most pronounced attenuation after 24h tended to be ones not expected to be
427 strongly engaged in the response to the pathogen type in the experiment. For instance, the
428 typically antiviral type I IFN pathway response was found to be markedly reduced in apes after
429 24 hours of bacterial but not viral stimulation. While the initial response of apes to immune
430 stimulus is very strong, temporal regulation of responding pathways may reduce the energetic
431 costs of such an immune strategy. What gene regulatory and immunological mechanisms are
432 involved in such temporal regulation will require further investigation.

433

434 In conclusion, we show initial antibacterial and antiviral responses of apes to be highly
435 correlated, and strongly responsive when compared to close relatives African and Asian
436 monkeys. Apes appear to have adopted an immune strategy that emphasizes sterilization over
437 specificity, strongly transcribing a greater number of genes in response to immune stimulation
438 and releasing very similar immune transcriptomic “arsenals” regardless of pathogen-type. This
439 powerful response dramatically shifts during the opening hours of infection, to involve
440 significantly fewer genes after 24 hours, which may help limit bystander tissue damage. The
441 energetically costly approach apes initiate in response to immune stimulation may be favored
442 by this primate family’s adoption of slower life history with increased risk of pathogen
443 exposure over reproductive life span, or past pathogen exposure. The addition of more primate
444 species, combined with the use of single-cell RNA sequencing methods are important next
445 steps to study the evolution of the immune system and more precisely map the immune cell
446 types that contribute the most to divergence in immune response across primates.

447

448

449

450 **Materials and methods**

451 **Sample collection and blood stimulation**

452 We measured innate immune responses on a panel of 6 humans, 6 chimpanzees, 6 rhesus
453 macaques, and 8 olive baboons (three females and 3 males for each species, 4 females, 4 males
454 for baboon). Human samples were obtained via informed consent, with the approval of the
455 Research Ethics Board at the Centre Hospitalier Universitaire Sainte-Justine (Research Ethics
456 Board approved protocol #3557). Non-human primate blood samples were humanely collected
457 in accordance with the animal subject regulatory standards of the Texas Biomedical Research
458 Institute and Emory University Institutional Animal Care and Use Committees. Chimpanzee
459 samples were collected prior to the NIH ban on chimpanzee research.

460

461 We drew 1 mL of whole blood from each animal directly into a TruCulture tube (Myriad RBM)
462 that contained: (i) cell culture media only (“control”), (ii) cell culture media plus 1 µg/mL ultra-
463 pure LPS from the *E. coli* 0111:B4 strain (“LPS”), or (iii) cell culture media plus 1 µg/mL of
464 Gardiquimod (“GARD”). Samples were incubated for 4 and 24 hours at 37°C. Following
465 incubation, we separated the plasma and cellular fractions centrifugation, and lysed and
466 discarded the red cells from the remaining cell pellet by applying red blood cell lysis buffer
467 (RBC lysis solution, 5 Prime Inc.) for 10 minutes followed by centrifugation and washing with
468 1x PBS. The remaining white blood cells were lysed in Qiazol and frozen at -80C until library
469 construction (Qiagen, San Diego, CA, USA). To control for variation in cellular composition
470 in downstream analyses, we used flow cytometry to quantify the proportions of leukocyte
471 subtypes, accounting for polymorphonuclear (CD14dim/SSC-A>100K/FSC-
472 A>100K/CD66+), classical monocytes (CD14+/CD16-), CD14+ intermediate monocytes
473 (CD14+/CD16+), CD14- non- classical monocytes (CD14-/CD16+), helper T cells
474 (CD3+/CD4+), cytotoxic T cells (CD3+/CD8+), double positive T cells (CD3+/CD4+/CD8+),
475 CD8- B cells (CD3-/CD20+/CD8-), CD8+ B cells (CD3-/CD20+/CD8+), natural killer T
476 lymphocytes (CD3+/CD16+), and natural killer cells (for monkeys: CD3-/CD16+ in the
477 lymphocyte scatter, for apes: CD3-/CD16+/CD56+ in the lymphocyte scatter) Samples for
478 FACS were simultaneously cleared of red blood cells vis lysis and fixed by application of BD
479 FACS-lyse for 2 minutes, prior to washing with 1x PBS, staining with fluorochrome
480 conjugated monoclonal antibodies (**Table S10**), before washing with 1x PBS and suspending
481 in a 1x PBS and paraformaldehyde solution for analysis on the BD LSRFortessa platforms.
482 Proportional analysis was completed in FlowJo X, using BD FACSBeads individually stained
483 with the antibodies to calculate compensation.

484

485 **RNA-seq data generation**

486 *Library construction.* Total RNA was isolated from cell lysate by phenol:chloroform
487 extraction and spin-column (miRNAeasy kit, Qiagen, San Diego, CA, USA), quantified by
488 spectrophotometry and assessed for quality using the Agilent 2100 bioanalyzer (Agilent
489 Technologies, Palo Alta, CA). Samples with no evidence of RNA degradation (Integrity
490 number >8) were then used for RNA library development. Messenger RNA (mRNA) was
491 isolated by magnetic bead and converted into RNA libraries using the Illumina TruSeq RNA
492 Library preparation kit v2 according to the manufacturer's instructions (Illumina, San Diego,
493 CA, USA). Libraries were sequenced on a HiSeq 2100, producing 151 transcriptomes, at 25-
494 30 million reads per sample

495 **Reads mapping on 1:1 orthologs**

496 Following sequencing, we trimmed Illumina adapter sequence from the ends of the reads and
497 remove bases with quality scores < 20 using Trim Galore (v0.2.7). We used STAR to align the
498 reads to an orthologous reference genome for all four species⁴⁷. We developed this genome
499 using the XSAnno pipeline which combines whole genome alignment, local alignment and
500 multiple filters to remove regions with difference in mappability between species⁴⁸. XSAnno
501 pipeline identifies orthologous genes across two species using three major filters namely
502 LiftOver to carry annotation of one species over the other, BLAT aligner to compare
503 orthologous exons identity between the two species and simNGS to identify exons that have
504 different lengths between the species. We used the genome assemblies of hg19 for human,
505 CHIMP2.1.4 for chimpanzee, MMUL 1.0 for macaque and PapAnu2.0 for olive baboon
506 species. We used human annotation as a reference. The pairwise alignment chains between
507 human and each species were obtained from UCSC genome browser.⁴⁹ We used different
508 thresholds to define orthologous regions between the two genomes to carry annotation from
509 one species to another using AnnoConvert program that utilize LiftOver according to
510 simulations using liftOverBlockSim PERL script from XSAnno pipeline⁵⁰. The values were
511 0.98, 0.92 and 0.91 for chimp, baboon and macaque respectively that were used to assign -
512 minMatch argument in AnnoConvert. Second step is using reciprocal whole genome alignment
513 using BLAT through BlatFilter software of the pipeline using annotations files generated
514 previously⁵¹. This step will filter exons that are highly divergent between the two species. The
515 last filter is using simNGS to simulate reads for exons assuming they are not differentially
516 expressed. Then, differential expression analysis is performed and if exons were found to be

517 differentially expressed, these will be filtered out as it reflects differential length of the exons
518 between species.

519

520 Gene expression estimates were obtained by summing the number of reads that mapped
521 uniquely to each species annotated genome using HTSeq-count (v0.6.1)⁵². After excluding
522 samples that did not produce sequenceable libraries and post-sequencing quality control, we
523 analyzed read counts for 151 samples (Humans: 12 controls, 12 LPS, 12 GARD; Chimpanzee:
524 12 controls, 12 LPS, 12 GARD; Rhesus: 11 controls, 12 LPS, 11 GARD; Baboons: 16 controls,
525 14 LPS, 15 GARD; **Table S1**). We confirmed the identity of all samples based on genotype
526 information derived from SNP calls made from the RNA-seq reads.

527 **Read normalization and filtering lowly expressed genes**

528 Prior to RNA-seq data analysis, we first filtered out genes that were very lowly or not
529 detectably expressed in our samples. Specifically, we only kept genes whose expression was
530 higher or equal to one count per million (CPM) in all the individuals from at least one species,
531 and one of the experimental conditions. This procedure yielded a total of 12,441 genes used
532 for further analysis. Normalization for sequencing depth and library sizes was done using
533 Trimmed Mean of M-values (TMM) method.⁵³ We normalized the resulting read count matrix
534 using the function *voom* from the R package *limma* to allow using linear models by *limma*
535 package.⁵⁴ The *voom* algorithm models mean-variance trend of logCPM for each gene and uses
536 it to compute the variance as a weight of logCPM values. We then modeled the normalized
537 expression values as a function of the different experimental factors in the study design such
538 as species, ligand and time points.

539 **Statistical analysis**

540 All statistical analysis was done on R version 3.6.2. Differential expression analysis was done
541 using *limma* package v.3.34.9.⁵⁵ We employed linear regression to identify DEGs according to
542 different questions asked by designing different models. We designated a model to test for
543 differences of gene expression across species and treatments, \sim covariates + species +
544 species:Time.point.stimulant. The arm Time.point.stimulant is the samples for each
545 experimental condition i.e. LPS.4h, LPS.24h, GARD.4h and GARD.24h. From this design, one
546 can retrieve ligand responses in each species right away, while responses to ligands at 24h are
547 built from linear combinations, such as (LPS.24h -NC.24h) and (GARD.24h -NC.24h). To take
548 into account the paired structure of the data, with different samples coming from the same

549 individuals, we used the duplicateCorrelation function. The used covariates are the different
550 cell proportions collected by the FACS data. The cell proportions covariates are aimed to
551 correct for the different proportion of white blood cells in different primate species since we
552 conducted the transcriptomic characterization on all immune white blood cells. Genes with
553 different magnitude of response between clades, referred to as clade differentially responsive
554 (c-DR) genes were characterized. We established two filters to characterize significant c-DR
555 genes in each treatment. Firstly, we required the genes not to be differentially responsive to the
556 treatment, even marginally, between within clade species pairs (chimpanzee vs human and baboon
557 vs macaque showing $FDR > 0.25$). Second, we required that any pairwise comparison involving
558 species from different clades to be significant at $FDR < 0.1$. Third, we also computed the average
559 differences in responses between apes and AAMs, as follows: the absolute difference between
560 the average response in apes vs AAMs, as follows:

561

$$562 \quad \frac{\log FC_{human} + \log FC_{chimpanzee}}{2} - \frac{\log FC_{macaque} + \log FC_{baboon}}{2}$$

563 And required that contrast to be significant at $FDR < 0.1$, with genes featuring

564

$$565 \quad \frac{|\log FC_{human} + \log FC_{chimpanzee}|}{2} - \frac{|\log FC_{macaque} + \log FC_{baboon}|}{2} > 0.5$$

566

567 being labeled ape-specific; and AAM-specific for those for which:

568

$$569 \quad \frac{|\log FC_{human} + \log FC_{chimpanzee}|}{2} - \frac{|\log FC_{macaque} + \log FC_{baboon}|}{2} < (-0.5)$$

570

571 Species-specific differentially responsive (s-DR) genes were identified using pairwise
572 comparisons at $FDR < 0.01$; consistent direction of expression in all contrasts, and systematic
573 differences corresponding to stronger, or weaker responses in the species of interest with
574 respect to the any of the other three. Finally, we also required genes to show a logFC in response
575 to the stimulus whose absolute differs in more than 1 log₂FC with respect to the average of the
576 other three animals. For humans, as an example, this means that:

577

$$578 \quad \left| \log FC_{human} - \frac{\log FC_{macaque} + \log FC_{baboon} + \log FC_{chimpanzee}}{3} \right| > 0.5$$

579

580

581 Ligand specific genes in each species are genes that are respond to one ligand (FDR<0.05), but
582 not to the other (FDR>0.25); and whose responses to both ligands are in turn significantly
583 different (FDR<0.05). Shared genes are those whose responses to ligands are both significant
584 (FDR<0.05 in both), and, at the same time, not significantly different between them
585 (FDR>0.25)

586 Correction of multiple testing was done using false discovery rate, FDR, as described by
587 Benjamini-Hochberg.⁵⁶

588

589 **Divergence scores**

590 For each time-point and stimulus, species were compared pairwise to retrieve the absolute
591 differences between species' responses to the stimulus under analysis. For the pair chimp vs
592 human, for example, we can define:

$$593 \quad \delta_{human.chimp} = |\log FC.human - \log FC.chimp|$$

594 Comparing these differences for pairs of animals within versus across clades, we obtained
595 divergence scores as follows:

596

$$597 \quad DS = \frac{\delta_{human.macaque} + \delta_{human.baboon} + \delta_{chimp.macaque} + \delta_{chimp.baboon}}{4}$$
$$598 \quad - \frac{\delta_{human.chimp} + \delta_{macaque.baboon}}{2}$$

599 The analysis was conducted for all 50 hallmark pathways. We restrict the analysis in a given
600 pathway to responsive genes (FDR < 0.05 in any species), whose average DS is reported. A p
601 value for each DS of a given pathway was calculated by contrasting the DSs of genes of this
602 specific pathway against the DSs of all responsive genes using Wilcoxon test.

603

604 **Functional characterization**

605 We conducted the functional characterization using gene ontology (GO) enrichment
606 implemented in CluGO application (2.5.5) of Cytoscape (v.3.7.2)⁵⁷ Benjamini-Hochberg
607 method for multiple correction was used and all orthologous genes, 12441 genes, were used as
608 a background. Default values were used for the rest of the parameters. FDR cut off use was
609 below 0.15.

610

611 **Data Availability**

612 The RNA-seq data generated in this study have been deposited in Gene Expression Omnibus
613 (accession number XXX).

614

615 **Author Contributions**

616 L.B.B. and J.F.B. designed research, M.B.F.H., J.F.B., J.K., J.S., J.C.G., Y.V., and L.B.B.
617 performed the research, M.B.F.H., J.C.G., J.F.B. and L.B.B. analyzed the data, M.B.F.H.,
618 J.F.B. and L.B.B. wrote the paper with contributions from all authors.

619

620 **Acknowledgements**

621 The authors thank Steven Bosinger, and Guido Silverstri of Yerkes Primate Center and Emory
622 University for their assistance acquiring samples. We thank L.B.B. laboratory members for
623 critical reading of the manuscript. We thank Calcul Québec and Compute Canada for providing
624 access to the supercomputer Briaree from the University of Montreal. This work was supported
625 by RGPIN/435917-2013 from the Natural Sciences and Engineering Research Council of
626 Canada (NSERC) and R01-GM134376 from the National Institute of General
627 Medical Sciences to L.B.B.. JFB is funded by NSF-BCS-1750675. The resources of the
628 Southwest and Yerkes National Primate Research Centers are supported by NIH grants P51-
629 OD011133 and P51-OD011132, respectively, from the Office of Research Infrastructure
630 Programs/Office of the Director

631

632

633

634

635 References

- 636 1 Redl, H., Bahrami, S., Schlag, G. & Traber, D. L. Clinical detection of LPS and animal
637 models of endotoxemia. *Immunobiology* **187**, 330-345, doi:10.1016/S0171-
638 2985(11)80348-7 (1993).
- 639 2 Munford, R. S. Sensing gram-negative bacterial lipopolysaccharides: a human disease
640 determinant? *Infect Immun* **76**, 454-465, doi:10.1128/IAI.00939-07 (2008).
- 641 3 Chahroudi, A., Bosinger, S. E., Vanderford, T. H., Paiardini, M. & Silvestri, G. Natural
642 SIV hosts: showing AIDS the door. *Science* **335**, 1188-1193,
643 doi:10.1126/science.1217550 (2012).
- 644 4 Sandmann, L. & Ploss, A. Barriers of hepatitis C virus interspecies transmission.
645 *Virology* **435**, 70-80, doi:10.1016/j.virol.2012.09.044 (2013).
- 646 5 Vaure, C. & Liu, Y. A comparative review of toll-like receptor 4 expression and
647 functionality in different animal species. *Front Immunol* **5**, 316,
648 doi:10.3389/fimmu.2014.00316 (2014).
- 649 6 Kumar, A. *et al.* Experimental human endotoxemia is associated with depression of
650 load-independent contractility indices: prevention by the lipid analogue E5531. *Chest*
651 **126**, 860-867, doi:10.1378/chest.126.3.860 (2004).
- 652 7 Taveira da Silva, A. M. *et al.* Brief report: shock and multiple-organ dysfunction after
653 self-administration of Salmonella endotoxin. *N Engl J Med* **328**, 1457-1460,
654 doi:10.1056/NEJM199305203282005 (1993).
- 655 8 Haudek, S. B. *et al.* Lipopolysaccharide dose response in baboons. *Shock* **20**, 431-436,
656 doi:10.1097/01.shk.0000090843.66556.74 (2003).
- 657 9 Yin, G. Q. *et al.* Endotoxic shock model with fluid resuscitation in *Macaca mulatta*.
658 *Lab Anim* **39**, 269-279, doi:10.1258/0023677054306926 (2005).
- 659 10 Akira, S. Pathogen recognition by innate immunity and its signaling. *Proc Jpn Acad*
660 *Ser B Phys Biol Sci* **85**, 143-156, doi:10.2183/pjab.85.143 (2009).
- 661 11 Barreiro, L. B., Marioni, J. C., Blekhman, R., Stephens, M. & Gilad, Y. Functional
662 comparison of innate immune signaling pathways in primates. *PLoS Genet* **6**,
663 e1001249, doi:10.1371/journal.pgen.1001249 (2010).
- 664 12 Brinkworth, J. F., Pechenkina, E. A., Silver, J. & Goyert, S. M. Innate immune
665 responses to TLR2 and TLR4 agonists differ between baboons, chimpanzees and
666 humans. *J Med Primatol* **41**, 388-393, doi:10.1111/jmp.12002 (2012).
- 667 13 Mandl, J. N. *et al.* Divergent TLR7 and TLR9 signaling and type I interferon production
668 distinguish pathogenic and nonpathogenic AIDS virus infections. *Nat Med* **14**, 1077-
669 1087, doi:10.1038/nm.1871 (2008).
- 670 14 Wlasiuk, G. & Nachman, M. W. Adaptation and constraint at Toll-like receptors in
671 primates. *Mol Biol Evol* **27**, 2172-2186, doi:10.1093/molbev/msq104 (2010).
- 672 15 van der Lee, R., Wiel, L., van Dam, T. J. P. & Huynen, M. A. Genome-scale detection
673 of positive selection in nine primates predicts human-virus evolutionary conflicts.
674 *Nucleic Acids Res* **45**, 10634-10648, doi:10.1093/nar/gkx704 (2017).
- 675 16 Danko, C. G. *et al.* Dynamic evolution of regulatory element ensembles in primate
676 CD4(+) T cells. *Nat Ecol Evol* **2**, 537-548, doi:10.1038/s41559-017-0447-5 (2018).
- 677 17 Rivera, A., Siracusa, M. C., Yap, G. S. & Gause, W. C. Innate cell communication kick-
678 starts pathogen-specific immunity. *Nat Immunol* **17**, 356-363, doi:10.1038/ni.3375
679 (2016).
- 680 18 Deschamps, M. *et al.* Genomic Signatures of Selective Pressures and Introgression
681 from Archaic Hominins at Human Innate Immunity Genes. *Am J Hum Genet* **98**, 5-21,
682 doi:10.1016/j.ajhg.2015.11.014 (2016).
- 683 19 Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
684 collection. *Cell Syst* **1**, 417-425, doi:10.1016/j.cels.2015.12.004 (2015).

- 685 20 Nunn, C. L., Gittleman, J. L. & Antonovics, J. Promiscuity and the primate immune
686 system. *Science* **290**, 1168-1170, doi:10.1126/science.290.5494.1168 (2000).
- 687 21 Nunn, C. L. A comparative study of leukocyte counts and disease risk in primates.
688 *Evolution* **56**, 177-190, doi:10.1111/j.0014-3820.2002.tb00859.x (2002).
- 689 22 Bradley, L. M., Dalton, D. K. & Croft, M. A direct role for IFN-gamma in regulation
690 of Th1 cell development. *J Immunol* **157**, 1350-1358 (1996).
- 691 23 Kak, G., Raza, M. & Tiwari, B. K. Interferon-gamma (IFN-gamma): Exploring its
692 implications in infectious diseases. *Biomol Concepts* **9**, 64-79, doi:10.1515/bmc-2018-
693 0007 (2018).
- 694 24 Zha, Z. *et al.* Interferon-gamma is a master checkpoint regulator of cytokine-induced
695 differentiation. *Proc Natl Acad Sci U S A* **114**, E6867-E6874,
696 doi:10.1073/pnas.1706915114 (2017).
- 697 25 Janeway, C. A., Jr. Approaching the asymptote? Evolution and revolution in
698 immunology. *Cold Spring Harb Symp Quant Biol* **54 Pt 1**, 1-13,
699 doi:10.1101/sqb.1989.054.01.003 (1989).
- 700 26 Matzinger, P. Tolerance, danger, and the extended family. *Annu Rev Immunol* **12**, 991-
701 1045, doi:10.1146/annurev.iy.12.040194.005015 (1994).
- 702 27 Brubaker, S. W., Bonham, K. S., Zanoni, I. & Kagan, J. C. Innate immune pattern
703 recognition: a cell biological perspective. *Annu Rev Immunol* **33**, 257-290,
704 doi:10.1146/annurev-immunol-032414-112240 (2015).
- 705 28 Fitzgerald, K. A. & Kagan, J. C. Toll-like Receptors and the Control of Immunity. *Cell*
706 **180**, 1044-1066, doi:10.1016/j.cell.2020.02.041 (2020).
- 707 29 Kanevskiy, L. M., Telford, W. G., Sapozhnikov, A. M. & Kovalenko, E. I.
708 Lipopolysaccharide induces IFN-gamma production in human NK cells. *Front*
709 *Immunol* **4**, 11, doi:10.3389/fimmu.2013.00011 (2013).
- 710 30 Ghosh, M., Subramani, J., Rahman, M. M. & Shapiro, L. H. CD13 restricts TLR4
711 endocytic signal transduction in inflammation. *J Immunol* **194**, 4466-4476,
712 doi:10.4049/jimmunol.1403133 (2015).
- 713 31 Kagan, J. C. *et al.* TRAM couples endocytosis of Toll-like receptor 4 to the induction
714 of interferon-beta. *Nat Immunol* **9**, 361-368, doi:10.1038/ni1569 (2008).
- 715 32 Harvey, P. H. & Clutton-Brock, T. H. Life History Variation in Primates. *Evolution* **39**,
716 559-581, doi:10.1111/j.1558-5646.1985.tb00395.x (1985).
- 717 33 Ross, C. Life history patterns and ecology and macaque species. *Primates* **33**, 207-215
718 (1992).
- 719 34 Wich, S. A. *et al.* Life history of wild Sumatran orangutans (*Pongo abelii*). *J Hum Evol*
720 **47**, 385-398, doi:10.1016/j.jhevol.2004.08.006 (2004).
- 721 35 Johnson, P. T. J. *et al.* Living fast and dying of infection: host life history drives
722 interspecific variation in infection and disease risk. *Ecology Letters* **15**, 235-242 (2012).
- 723 36 Cronin, J. P., Welsh, M. E., Dekkers, M. G., Abercrombie, S. T. & Mitchell, C. E. Host
724 physiological phenotype explains pathogens reservoir potential *Ecology Letters* **13**,
725 1221-1232 (2010).
- 726 37 Buechler, C. R. *et al.* Seroprevalence of Zika Virus in Wild African Green Monkeys
727 and Baboons. *mSphere* **2**, doi:10.1128/mSphere.00392-16 (2017).
- 728 38 Gao, F. *et al.* Origin of HIV-1 in the chimpanzee *Pan troglodytes* troglodytes. *Nature*
729 **397**, 436-441, doi:10.1038/17130 (1999).
- 730 39 Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H. & Johnson, P. R. An
731 African primate lentivirus (SIVsm) closely related to HIV-2. *Nature* **339**, 389-392,
732 doi:10.1038/339389a0 (1989).

- 733 40 Vasilakis, N., Cardoso, J., Hanley, K. A., Holmes, E. C. & Weaver, S. C. Fever from
734 the forest: prospects for the continued emergence of sylvatic dengue virus and its impact
735 on public health. *Nat Rev Microbiol* **9**, 532-541, doi:10.1038/nrmicro2595 (2011).
- 736 41 Okin, D. & Medzhitov, R. Evolution of inflammatory diseases. *Curr Biol* **22**, R733-
737 740, doi:10.1016/j.cub.2012.07.029 (2012).
- 738 42 Sorci, G., Cornet, S. & Faivre, B. Immune evasion, immunopathology and the
739 regulation of the immune system. *Pathogens* **2**, 71-91, doi:10.3390/pathogens2010071
740 (2013).
- 741 43 Ito, J., Gifford, R. J. & Sato, K. Retroviruses drive the rapid evolution of mammalian
742 APOBEC3 genes. *Proc Natl Acad Sci U S A* **117**, 610-618,
743 doi:10.1073/pnas.1914183116 (2020).
- 744 44 Enard, D., Cai, L., Gwennap, C. & Petrov, D. A. Viruses are a dominant driver of
745 protein adaptation in mammals. *Elife* **5**, doi:10.7554/eLife.12469 (2016).
- 746 45 Harrison, G. F. *et al.* Natural selection contributed to immunological differences
747 between hunter-gatherers and agriculturalists. *Nat Ecol Evol* **3**, 1253-1264,
748 doi:10.1038/s41559-019-0947-6 (2019).
- 749 46 Morris, M. C., Gilliam, E. A. & Li, L. Innate immune programming by endotoxin and its
750 pathological consequences. *Front Immunol* **5**, 680, doi:10.3389/fimmu.2014.00680
751 (2014).
- 752 47 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21,
753 doi:10.1093/bioinformatics/bts635 (2013).
- 754 48 Zhu, Y., Li, M., Sousa, A. M. & Sestan, N. XSAnno: a framework for building ortholog
755 models in cross-species transcriptome comparisons. *BMC Genomics* **15**, 343,
756 doi:10.1186/1471-2164-15-343 (2014).
- 757 49 Kent, W. J. *et al.* The human genome browser at UCSC. *Genome Res* **12**, 996-1006,
758 doi:10.1101/gr.229102 (2002).
- 759 50 Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic
760 Acids Res* **34**, D590-598, doi:10.1093/nar/gkj144 (2006).
- 761 51 Kent, W. J. BLAT--the BLAST-like alignment tool. *Genome Res* **12**, 656-664,
762 doi:10.1101/gr.229202 (2002).
- 763 52 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
764 throughput sequencing data. *Bioinformatics* **31**, 166-169,
765 doi:10.1093/bioinformatics/btu638 (2015).
- 766 53 Robinson, M. D. & Oshlack, A. A scaling normalization method for differential
767 expression analysis of RNA-seq data. *Genome Biol* **11**, R25, doi:10.1186/gb-2010-11-
768 3-r25 (2010).
- 769 54 Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear
770 model analysis tools for RNA-seq read counts. *Genome Biol* **15**, R29, doi:10.1186/gb-
771 2014-15-2-r29 (2014).
- 772 55 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-
773 sequencing and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007
774 (2015).
- 775 56 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
776 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series
777 B (Methodological)* **57**, 289-300 (1995).
- 778 57 Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene
779 ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-1093,
780 doi:10.1093/bioinformatics/btp101 (2009).
- 781

782 **Supplementary Tables**

783

784 **Table S1:** Summary of all samples included in this study and associated metadata.

785

786 **Table S2:** Pairwise comparisons of cell population proportions between primate species.

787

788 **Table S3:** Summary of log2FC and FDR for all orthologs for all species across all treatments.

789

790 **Table S4:** Conserved genes that are responding in all species in LPS and GARD 4h treatments.

791

792 **Table S5:** Clade differentially responsive genes across all treatments.

793

794 **Table S6:** Divergence scores and p values for all hallmark pathways in all treatments.

795

796 **Table S7:** Species-specific differentially responsive genes. Two sets are provided for every
797 species, genes with higher response in this species vs. all other species
798 (species.DRSG.higherRes) and genes with lowest response compared to all other species
799 (species.DRSG.lowerRes).

800

801 **Table S8:** Gene ontology enrichment analysis of all clade and species specific differentially
802 responsive genes.

803

804 **Table S9:** List of genes underwent temporal reduction or increase in response at later time
805 point in each species and treatment (LPS and GARD).

806

807 **Table S10:** List of antibodies used to characterize primate's leukocytes composition.

808

809

810

811

812

813

814

815